The Phase III trial of Merck & Co., Inc. and Daiichi Sankyo Co., Ltd.’s ifinatamab deruxtecan (I-DXd) in small-cell lung cancer (SCLC) will report in 2027, and following the recent misfire with another of the partners’ antibody-drug conjugates, patritumab deruxtecan, they need this one to hit.
Merck & Co. and Daiichi’s Phase II ADC Hit Raises Expectations
Ifinatamab deruxtecan, a potential first-in-class B7-H3-targeted conjugate, looks promising – but the real test is to come.
More from Clinical Trials
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
More from R&D
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.